A new era in cancer research
Analyze 7M+ patient journeys across 100+ cancers
Study common and rare cancers with unmatched breadth
Truveta provides complete, regulatory grade EHR data – linked to closed claims, mortality, and tumor genetics – to power timely research across the full spectrum of cancer types, from high-prevalence to rare.
Sample of cancers represented in Truveta Data
Hover to see population counts
Breast
1.1M
total population
Gastric
70K
total population
Colorectal
459K
total population
Prostate
862K
total population
Non-Hodgkin Lymphoma
391K
total population
Oropharyngeal
170K
total population
Glioblastoma
20K
total population
Cervical
122K
total population
Liver
123K
total population
Lung
652K
total population
Thyroid
191K
total population
Melanoma
432K
total population
A
- Acinar cell carcinoma
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Adenocarcinoma
- Anal cancer
- Anaplastic thyroid cancer
- Angiosarcoma of the liver
B
- Basal cell carcinoma
- Bladder cancer
- Bone sarcomas – Chondrosarcoma
- Bone sarcomas – Ewing sarcoma
- Bone sarcomas – Osteosarcoma
C
- Cervical cancer
- Cholangiocarcinoma (bile duct cancer)
- Chromophobe renal cell carcinoma
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- Clear cell renal cell carcinoma
- Collecting duct carcinoma
- Cutaneous T-cell lymphoma
D
- Ductal carcinoma in situ (DCIS)
E
- Epithelial ovarian cancers – Clear cell carcinoma
- Epithelial ovarian cancers – Endometrioid carcinoma
- Epithelial ovarian cancers – Mucinous carcinoma
- Epithelial ovarian cancers – Serous carcinoma (high-grade and low-grade)
F
- Familial adenomatous polyposis (FAP)
- Fibrolamellar carcinoma
- Follicular thyroid cancer
G
- Gallbladder cancer
- Germ cell tumors
- Gliomas – Astrocytoma
- Gliomas – Glioblastoma
- Gliomas – Oligodendroglioma
H
- Hairy cell leukemia
- Hepatoblastoma
- Hepatocellular carcinoma
- HER2-positive breast cancer
- Hodgkin lymphoma – Lymphocyte-depleted
- Hodgkin lymphoma – Lymphocyte-rich
- Hodgkin lymphoma – Mixed cellularity
- Hodgkin lymphoma – Nodular sclerosis
- Hormone receptor-positive breast cancer
- Hurthle cell carcinoma
- Hypopharyngeal cancer
I
- IgA myeloma
- IgG myeloma
- Inflammatory breast cancer
- Invasive ductal carcinoma (IDC)
- Invasive lobular carcinoma (ILC)
L
- Laryngeal cancer
- Light chain myeloma
- Lynch syndrome
M
- Medullary carcinoma
- Medullary thyroid cancer
- Medulloblastoma
- Melanoma – Acral lentiginous
- Melanoma – Lentigo maligna
- Melanoma – Nodular
- Melanoma – Superficial spreading
- Meningioma
- Merkel cell carcinoma
- Mucinous adenocarcinoma
N
- Nasopharyngeal cancer
- Neuroendocrine tumors
- Non-Hodgkin lymphoma – Burkitt lymphoma
- Non-Hodgkin lymphoma – Diffuse large B-cell lymphoma
- Non-Hodgkin lymphoma – Follicular lymphoma
- Non-Hodgkin lymphoma – Mantle cell lymphoma
- Non-Hodgkin lymphoma – Marginal zone lymphoma
- Non-secretory myeloma
- Non-small cell lung cancer (NSCLC) – Adenocarcinoma
- Non-small cell lung cancer (NSCLC) – Large cell carcinoma
- Non-small cell lung cancer (NSCLC) – Squamous cell carcinoma
O
- Oral cavity cancer
- Oropharyngeal cancer
P
- Paget’s disease of the breast
- Pancreatic ductal adenocarcinoma
- Pancreatic neuroendocrine tumors (PNETs) – Gastrinoma
- Pancreatic neuroendocrine tumors (PNETs) – Glucagonoma
- Pancreatic neuroendocrine tumors (PNETs) – Insulinoma
- Pancreatic neuroendocrine tumors (PNETs) – Non-functioning PNETs
- Papillary renal cell carcinoma
- Papillary thyroid cancer
- Pituitary adenomas
- Plasma cell leukemia
R
- Renal medullary carcinoma
- Retinoblastoma
S
- Salivary gland cancers – Acinic cell carcinoma
- Salivary gland cancers – Adenoid cystic carcinoma
- Salivary gland cancers – Mucoepidermoid carcinoma
- Schwannomas
- Sex cord-stromal tumors
- Signet ring cell carcinoma
- Small cell lung cancer (SCLC) – Combined small cell carcinoma
- Small cell lung cancer (SCLC) – Small cell carcinoma
- Smoldering multiple myeloma
- Soft tissue sarcomas – Angiosarcoma
- Soft tissue sarcomas – Leiomyosarcoma
- Soft tissue sarcomas – Liposarcoma
- Soft tissue sarcomas – Rhabdomyosarcoma
- Soft tissue sarcomas – Synovial sarcoma
- Squamous cell carcinoma
T
- Triple-negative breast cancer
W
- Wilms tumor (pediatric)
See the full patient journey across all sites of care
Truveta Data includes over 7M cancer patient journeys – nearly double the scale of leading competitors – capturing care before, during, and after diagnosis across oncology and non-oncology settings. It captures care wherever it happens, with rich clinical detail from EHRs, including notes and imaging, plus linked claims and genetics.
Extract essential insights from notes and images
The Truveta Language Model enables access to critical oncology data from clinical notes – including progression, line of therapy, treatment response, and reasons for discontinuation.
Paired with 100M+ medical images across modalities like CT, MRI, and PET, researchers can track how cancer evolves and uncover what drives treatment decisions.
Diagnosis and recent HPI
Tumor size
Histology findings
Tumor staging
FIGO stage
Overall clinical assessment
Generate evidence faster and with confidence
Truveta Data is updated daily – so you can study yesterday’s care today – and exceeds FDA standards for quality, provenance, and auditability. From R&D and clinical trials to HEOR, safety, and closing care gaps, Truveta supports the full clinical and economic journey, from diagnosis through long-term outcomes.
Example: Closing care gaps in colorectal cancer screening
Study using Truveta Data to identify disparities in adherence to stool-based colorectal cancer screening by age, race, and provider type – informing efforts to close gaps in preventive care.
Explore whitepapers
Truveta Language Model
Data quality
Data security
